TABLE II.

Baseline participant characteristics by dosing eligibility status

	Eligible	Ineligible			P values*
	(1)	(2) IgE <30 IU/mL	(3) IgE/weight	(4) IgE >1300 IU/mL	(1) vs (2), (3) & (4)	(1) vs (2)	(1) vs (3) & (4)
No. of participants	596	83	107	103
Age (y), mean ± SD	10.7 ± 3.6	10.1 ± 3.9	11.0 ± 3.4	14.0 ± 3.0	<.001	.10	<.001
Symptoms, mean ± SD
Nights awoken (past 4 wk)	11.5 ± 6.7	11.2 ± 6.6	11.3 ± 7.3	11.4 ± 6.9	.80	.58	.99
Days of wheeze (past 2 wk)	4.3 ± 2.2	4.2 ± 2.3	4.7 ± 2.2	4.5 ± 2.2	.39	.53	.15
No. of albuterol uses (past 2 wk)	14 ± 11	14 ± 12	14 ± 12	16 ± 12	.88	.68	.66
Health care utilization in past year (%)
Any hospitalizations	28	12	25	25	.03	<.01	.32
Any unscheduled visits	81	91	84	84	.13	.02	.60
On daily controller medications	89	78	85	85	.06	<.01	.42
Allergen skin tests
No. positive (of 14), mean ± SD	4.4 ± 2.7	2.6 ± 2.1	5.6 ± 2.8	5.6 ± 2.8	.20	<.001	<.001
Dog (%)	30	19	29	35	.49	.03	.67
Cat (%)	52	21	65	66	.75	<.001	<.001
Mouse (%)	31	15	49	41	.15	<.01	<.001
Der f (%)	38	27	58	57	<.01	.07	<.001
Der p (%)	45	28	63	56	.13	<.01	<.001
German roach (%)	50	17	61	62	.70	<.001	<.01
Roach mix (%)	52	30	65	68	.25	<.001	<.001

^*The 3 P values test for differences between: eligible and all ineligible participants, eligible participants and participants who were excluded because of low IgE, and eligible participants and participants who were excluded because of either high IgE or a combination of weight and IgE.